Lifen Wang
Impact in
-
- Hepatitis C virus research
- Nephrology top 10%
- Acute Kidney Injury Research
- Gout, Hyperuricemia, Uric Acid
Papers in
-
- Hepatitis B Virus Studies 5
- Liver Disease Diagnosis and Treatment 2
- Multiple and Secondary Primary Cancers 1
- Co-authors
- Zhiming Ye (5 shared papers)Zhilian Li (2 shared papers)Xinling Liang (2 shared papers)Ruizhao Li (1 shared paper)Wei Dong (1 shared paper)Asrar B. Malik (1 shared paper)Li Zhang (1 shared paper)Wei Shi (1 shared paper)
- Journals
- Medicine (2 papers)Microbiology Spectrum (1 paper)Hepatology International (1 paper)European Journal of Endocrinology (1 paper)Journal of Viral Hepatitis (1 paper)
- Partner nations
- ChinaUnited StatesBelgium
In The Last Decade
Lifen Wang
16 papers receiving 189 citations
Peers
Comparison fields: 5 of 42
- Hepatology 44
- Nephrology 40
- Epidemiology 71
- Molecular Biology 70
- Immunology 18
Countries citing papers authored by Lifen Wang
This map shows the geographic impact of Lifen Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lifen Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lifen Wang more than expected).
Fields of papers citing papers by Lifen Wang
This network shows the impact of papers produced by Lifen Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lifen Wang. The network helps show where Lifen Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lifen Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 74 | |
| 2 | 2006 | 41 | |
| 3 | Prevalence of abnormal glycometabolism in patients with chronic hepatitis C and related risk factors in China. | 2011 | 11 |
| 4 | 2023 | 9 | |
| 5 | 2020 | 9 | |
| 6 | The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication. | 2016 | 8 |
| 7 | 2013 | 7 | |
| 8 | 2019 | 6 | |
| 9 | 2021 | 5 | |
| 10 | 2020 | 5 | |
| 11 | [Association of heart valve calcification with cardiovascular outcomes in patients on maintenance hemodialysis]. | 2016 | 4 |
| 12 | Optimized tandem amiRNA mediates stronger inhibitory effects on hepatitis B virus infection. | 2011 | 4 |
| 13 | 2024 | 2 | |
| 14 | [Expression of CD68 CD45RO CD20 and proliferating cell nuclear antigen in nasal polyps]. | 2003 | 2 |
| 15 | 2018 | 2 | |
| 16 | [Diagnostic value of urine HBV DNA for hepatitis B virus-associated glomerulonephritis]. | 2014 | 1 |
| 17 | Epidemiology and natural history of primary biliary cirrhosis | 2015 | 0 |
| 18 | 2025 | 0 |
About Lifen Wang
Lifen Wang is a scholar working on Epidemiology, Molecular Biology, Endocrinology, Diabetes and Metabolism, Hepatology and Nephrology, having authored 18 papers that have together received 190 indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (5 papers), Liver Disease Diagnosis and Treatment (2 papers), Thyroid Cancer Diagnosis and Treatment (2 papers), Hepatitis C virus research (2 papers), Multiple and Secondary Primary Cancers (1 paper), Inflammatory Biomarkers in Disease Prognosis (1 paper), Liver Diseases and Immunity (1 paper) and Sinusitis and nasal conditions (1 paper). The work is most often cited by research in Hepatology (44 citations), Nephrology (40 citations), Epidemiology (71 citations), Molecular Biology (70 citations) and Immunology (18 citations). Lifen Wang has collaborated with scholars based in China, United States and Belgium. Frequent co-authors include Zhiming Ye, Zhilian Li, Xinling Liang, Ruizhao Li, Wei Dong, Asrar B. Malik, Li Zhang, Wei Shi, Kwong Tai Cheng and Hongguang Zhu. Their work appears in journals such as Medicine, Microbiology Spectrum, Hepatology International, European Journal of Endocrinology and Journal of Viral Hepatitis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.